KELUN PHARMA: The company's products are expected to win bids in the 11th batch of national centralized drug procurement

KELUN PHARMA announced that the company and its subsidiaries participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. The company's products, Malate Avarbital Tablets, Avarbital Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets are expected to win bids. Among them, the sales revenue of Avarbital Ethanolamine Tablets for the year 2024 is expected to be 19.9423 million yuan, and the sales revenue of Compound Sodium Acetate Ringer's Injection for the year 2023 is expected to be 17.7263 million yuan, with a sales revenue of 7.9331 million yuan for the year 2024